Table 1.
Comparisons of clinical and laboratory features between the remission and relapse groups
| Remission (n = 104) | Relapse (n = 38) | p | |
|---|---|---|---|
| Age, years | 47±12 | 45±13 | n.s. |
| Women | 69 (66.3) | 26 (68.4) | n.s. |
| Treatment duration, months | 27±22 | 26±23 | n.s. |
| Follow-up duration, months | 49±26 | 57±24 | n.s. |
| Follow-up duration since withdrawal of ATD, months | 20±8 | 29±12 | <0.001 |
| Pretreatment large goiter (>40 g) | 19 (18.3) | 5 (13.2) | n.s. |
| Posttreatment goiter decrease (>30%) | 46 (44.2) | 11 (28.9) | n.s. |
| Ophthalmopathy | 11 (10.6) | 5 (13.2) | n.s. |
| Pretreatment serum T3, nmol/l | 3.6 (2.7–4.6) | 3.7 (2.9–4.9) | n.s. |
| Pretreatment serum free T4, pmol/l | 37 (30–45) | 35 (28–50) | n.s. |
| Pretreatment serum TSH, mU/l | 0.01 (0.01–0.03) | 0.01 (0.01–0.04) | n.s. |
| Pretreatment serum TRAb, IU/l | 39.3 (10.6–74.4) | 28.4 (6.0–58.0) | n.s. |
| Pretreatment high TRAb (>30 IU/l) | 60 (57.7) | 21 (55.3) | n.s. |
| Posttreatment serum TRAb, IU/l | 0.6 (0.2–1.6) | 0.8 (0.3–3.7) | n.s. |
| History of retreatment after relapse | 28 (26.9) | 18 (47.4) | 0.02 |
| UIC, μg/l | 412 (187–1,438) | 408 (272–1,274) | n.s. |
| Urine I/Cr, μg/g Cr | 309 (146–948) | 320 (145–1,079) | n.s. |
Data expressed as n (%), means ± SD, or medians (interquartile range). n.s. = Not significant.